DeForge v. GlaxoSmithKline, LLC
DeForge v. GlaxoSmithKline, LLC
Trial Court Opinion
UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION <AES DIST, Certified to be a true and LS Ee. <CoN correct copy of the document on file □□ paNe\ Noble, Clerk, IN RE: ZANTAC (RANITIDINE) PRODUCTS ay, A Spee onde LIABILITY LITIGATION 3! MAP S} 5, J. Adams MDL No. 2924 CONN aii Dep aH DisTRICt Date___Apr 9, 20 (SEE ATTACHED SCHEDULE)
CONDITIONAL TRANSFER ORDER (CTO -125)
On February 6, 2020, the Panel transferred 12 civil action(s) to the United States District Court for the Southern District of Florida for coordinated or consolidated pretrial proceedings pursuant to
28 U.S.C. § 1407. See
437 F.Supp.3d 1368(J.P.M.L. 2020). Since that time, 437 additional action(s) have been transferred to the Southern District of Florida. With the consent of that court, all such actions have been assigned to the Honorable Robin L. Rosenberg. It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the Southern District of Florida and assigned to Judge Rosenberg. Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under
28 U.S.C. § 1407to the Southern District of Florida for the reasons stated in the order of February 6, 2020, and, with the consent of that court, assigned to the Honorable Robin L. Rosenberg. This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the Southern District of Florida. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this □□□□□ period, the stay will be continued until further order of the Panel.
— FOR THE PANEL: pending athe, Me ° oe Apr 09, 2024 UaeD Ses Tiffaney D. Pete MULTIDISTRICT LITIGATION Clerk of the Panel
Case MDL No. 2924 Document 1438 Filed 04/09/24 Page 2 of 2 IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION MDL No. 2924 SCHEDULE CTO−125 − TAG−ALONG ACTIONS
DIST DIV. C.A.NO. CASE CAPTION
CALIFORNIA NORTHERN CAN 3 24−01835 Hart v. GlaxoSmithKline, LLC et al CAN 3 24−01880 Berghoff v. GlaxoSmithKline, LLC et al CAN 3 24−01903 DeForge v. GlaxoSmithKline, LLC et al OKLAHOMA WESTERN OKW 5 24−00312 Oldham v. Sanofi−Aventis US LLC et al
Reference
- Status
- Unknown